Commentary: When cancer is oligometastatic, even mesothelioma is curable.

Abbas E. Abbas, MD, MS, FACS

Cure is possible in oligometastatic disease even for aggressive cancers such as mesothelioma. Whenever present oligometastatic disease should be considered for complete eradication if deemed possible.

See Article page 358.

Malignant pleural mesothelioma (MPM) is an uncommon and predictably fatal disease. It affects about 3200 people per year in the United States and, after diagnosis, the median survival is between 12 and 18 months whereas the 5-year survival rate is less than 5%. Despite its aggressive and deadly nature, MPM is relatively unique in that the cause of death is typically from local extension and recurrence, not from systemic metastasis. According to one study, the most common modes of failure after trimodality therapy for MPM are local recurrence in the ipsilateral hemithorax (35%), abdomen (26%), and contralateral thorax (17%).

Because of this behavior, many assume that distant metastases from MPM are unusual. In fact it is quite the opposite, since autopsy studies show that the majority of patients have hematogenous secondaries at the time of death, most commonly to the abdominal viscera. Brain metastasis is much less common (2.7%) and only rarely is it in the form of a solitary lesion., Interestingly, no brain metastases have been described in cases of peritoneal mesothelioma, a disease with a much more favorable outcome than its pleural counterpart.

Li and colleagues presented a case report of a patient with epithelioid MPM who maintained disease-free survival 3.5 years after resection of a solitary brain metastasis that presented more than 2 years after radical pleurectomy. The fact that this paper is deserving of publication highlights the rarity of this condition. It sits among very few similar reports, such as that by Kitai and colleagues in 1995, who reported a similar patient with no recurrence 3 years after resection of a solitary brain metastasis that presented 1 year after radical pleurectomy for epithelioid MPM.

These and similar reports capture our attention due to their rarity in an already-rare and lethal disease. However, maybe the focus should instead be on the state of oligometastatic disease rather than the histology of the primary malignancy. This concept of “oligometastasis” is fairly recent, having been coined in 1995 by Hellman and Weichselbaum. They hypothesized that oligometastasis is an intermediate state between localized and systemically metastasized disease. It is believed that the biology of oligometastatic tumors may be different and more favorable than that of tumors with more widespread metastases., Since inception of this hypothesis of oligometastasis as a potentially curable disease, 2 other concepts have been proposed; oligorecurrence and oligoprogression. Oligorecurrence refers to 1 or fewer distant metastases after control of the primary tumor. Oligoprogression, in contrast, is when diffuse metastases manifest progression in only a few lesions while the rest remain stable.

There has been much debate on what defines oligometastasis in regard to the number and location of the lesions. However, what truly distinguishes oligometastatic disease is that the lesions must all be amenable to eradication or local consolidative therapy (LCT) by either surgery or ablation, providing the possibility of disease-free survival. In evaluating oligometastatic lesions for LCT, the risk factors for failure and recurrence include a short initial disease-free state and multiplicity of lesions. There is also debate on whether LCT is only justifiable in certain cancers that behave better than others, eg, colorectal cancer and sarcoma., However, and increasingly, reports have described improved survival and long-term cures after LCT for oligometastatic tumors not typically considered responsive to this form of therapy, such as malignant melanoma, breast cancer, esophageal cancer, pancreatic cancer, mesothelioma, and others.,17, 18, 19, 20

Perhaps what we do learn most from these success stories is to not withhold curative therapy in metastatic disease solely based on histology or organ of origin, especially when there has been a long disease-free state and a small number of metastatic lesions. Conceivably, it should be an expectation, not a surprise, when patients who develop limited metastases do well when aggressive measures are taken to rid them of all metastatic disease. Indeed, regardless of histology of primary tumor and as aptly stated by Kaneda and Saito, oligometastases should be defined by prognosis and evaluated by cure. Whenever present, oligometastases should always be carefully considered for LCT when complete eradication is deemed possible.